Nasus Pharma said that data from the first cohort dosed in its Phase 2 clinical study of NS002 epinephrine nasal powder demonstrate greater mean peak plasma concentration and faster time to peak concentration for the intranasal formulation compared to intramuscular injection of epinephrine via EpiPen autoinjector. In addition, 91% of participants who received NS002 reached 100 pg/ml plasma concentration after 5 minutes compared to 67% of participants who received EpiPen injection.
According to Nasus, data from the first 25 participants dosed demonstrated a Cmax of 655 pg/ml for NS002 versus 548 pg/ml for EpiPen and Tmax of 10.8 minutes for NS002 versus 15 minutes for EpiPen. The study includes repeated doses of NS002, with and without nasal allergen challenge. Nasus says that results were consistent irrespective of nasal allergen challenge.
As for the PD data, the company says that, “The pharmacodynamic response, including changes from baseline in systolic and diastolic blood pressure and pulse rate, was comparable to that of EpiPen and remained within the normal range.”
Nasus announced initiation of the Phase 2 trial in November 2025 and says that it expects the study to be completed by the end of the first quarter of this year, with data from all fifty participants reported in the final results. NS002 is delivered via Aptar Pharma’s UDS nasal powder delivery device.
Nasus Pharma CEO Dan Teleman commented, “We are extremely pleased with these positive interim results, which we believe further validate NS002’s potential as a first-in-class intranasal powder epinephrine product for patients with severe allergies. The sustained performance of NS002 across single and repeat dosing scenarios, including under conditions simulating real-world allergic reactions, demonstrates the robustness of our proprietary Nasax platform technology. We look forward to completing the Phase 2 study and advancing to our pivotal clinical program.”
Read the Nasus Pharma press release
